House GOP Healthcare Bill Advances Amid Imminent ACA Subsidy Expiration

House Republicans are preparing to vote on their healthcare bill amid the impending expiration of enhanced Affordable Care Act (ACA) subsidies. The bill does not include provisions to extend these premium subsidies, which were implemented in 2021 as part of a COVID-19 relief package. With the Senate unlikely to vote on healthcare proposals this week and recent Senate votes rejecting measures to extend the subsidies, the enhanced financial assistance to ACA enrollees is expected to expire at the end of the year. If this occurs, average premium costs for enrollees are projected to increase by 114%, or about $1,000 annually in 2026, potentially leading to approximately 2 million more uninsured individuals, according to the Congressional Budget Office. The House Republican bill incorporates several long-standing GOP health care initiatives, including expanding association health plans (AHPs). These plans would allow small businesses and self-employed individuals to join together across industries to purchase coverage, aiming to lower premiums. While AHPs cannot exclude individuals with preexisting conditions or charge higher premiums based on these conditions, they are not required to offer the same comprehensive coverage as ACA plans and can impose higher premiums on older enrollees, which may affect risk pooling and market stability. The legislation also proposes reinstating federal funding for cost-sharing subsidies that help lower-income ACA enrollees with deductibles and out-of-pocket costs. Although funding these subsidies may reduce silver plan premiums, it simultaneously decreases the overall aid available to consumers, potentially raising monthly premium payments. Additionally, the bill directs that these subsidies cannot fund plans covering abortion services, making the proposal politically contentious in the Senate. Transparency reforms in the pharmaceutical supply chain are another key feature of the bill. Specifically, it requires pharmacy benefit managers (PBMs) to disclose drug prices, rebates, and other transactional data to employers, aiming to increase transparency surrounding drug costs. Nonetheless, industry analysts suggest that these disclosures may have limited impact on lowering medication prices. Finally, the bill seeks to codify existing regulations allowing employers to provide workers with tax-free funds to purchase coverage on ACA exchanges. Critics warn this could lead to adverse selection with sicker employees in ACA plans, potentially driving premium increases and shifting risk to employees if employer contributions fail to keep pace with rising costs. Overall, the House GOP healthcare bill focuses on a mix of premium cost strategies, market structure changes, and regulatory transparency initiatives, set against the backdrop of significant uncertainty regarding the future of ACA premium subsidies.